13yr
In production,
continuously
continuously
Most genomic results — pharmacogenomics, hereditary risk, carrier status — are delivered as a PDF and never seen again. ActX turns them into computable, patient-specific decision support, live inside the EHR at the point of care. In production across 10 EHRs, 560+ provider sites, 44 states.
The industry generated the data — millions of patients tested for drug response, hereditary risk, and carrier status. But a result delivered as a PDF is un-computable and unsearchable: it can't drive an alert, can't be checked against a new prescription two years later, can't reach the clinician at the moment of the decision.
The science ends up in the chart and still changes nothing. Testing was the achievable part. Translation — turning a static report into something that acts inside the workflow — is what the industry never solved.
ActX is genomics decision support — not a lab. It's the computable layer that sits on top of every lab, turning whatever they produce into action at the point of care.
ActX ingests genomic results from any lab, normalizes them into computable intelligence, and delivers patient-specific guidance natively inside the EHR — checking every new prescription against the patient's genome in real time, and surfacing hereditary risk and carrier status when they are clinically relevant. No new tab, no new login, no PDF to dig up.
It is the operational layer precision medicine has been missing: the same genomic data, finally turned from a report nobody reopens into guidance a clinician acts on at the moment it matters.
These are not pilots. They are live genomic integrations carrying real patient volume, with the kind of client tenure that only accrues when clinicians keep the alerts turned on.
Live, bidirectional EHR integration. Genomic curation across pharmacogenomics, hereditary risk, and carrier status. Alert logic clinicians don't reflexively dismiss. A deployed base that already trusts the system. Each is slow on its own; together they are a multi-year program with a long tail of partnership and credibility that cannot be bought off a shelf.
Rebuilding it is a roadmap. Acquiring it is a transaction.
Structured, computable genomics no LLM can infer from a scanned report — plus the proven rail to deliver it into care.
Fewer adverse events and ineffective scripts, flagged at the point of decision instead of in a retrospective report.
Convert the static reports you already produce into longitudinal, in-workflow clinical value your customers act on.
A proven point-of-care genomics capability, delivered rather than staffed and built over years.
A mature, in-production genomic operationalization capability is available for a fraction of the capital invested to build it — and well below what it would cost any acquirer to build the same thing from zero. The window is short.
Request the confidential overview →